Kestra Medical Technologies general counsel sells $2.7m in shares

Traci S. Umberger, General Counsel and Chief Administrative Officer at Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), sold common shares totaling $2,718,318 on October 21, 2026. The transactions were executed as part of a Rule 10b5-1 trading plan, which was adopted on July 21, 2026.

Ms. Umberger disposed of 96,404 common shares at weighted average prices ranging from $26.8050 to $27.7927 per share. Separately, an additional 3,596 common shares were sold at weighted average prices between $27.8200 and $28.4200 per share.

Prior to these sales, Ms. Umberger acquired 100,000 common shares through the exercise of options at a price of $17.00 per share, totaling $1,700,000. Following these reported transactions, Ms. Umberger beneficially owns 195,825 common shares directly.Investors tracking insider activity at Kestra Medical can access comprehensive analysis through InvestingPro, which offers detailed Pro Research Reports for over 1,400 US equities. These reports transform complex Wall Street data into clear, actionable intelligence, helping investors understand what insider transactions might signal about a company’s prospects.

In addition to the common shares, Ms. Umberger holds 441,000 derivative securities in the form of options. Of these, 395,919 are fully vested, with the remaining 45,081 options scheduled to vest in equal monthly installments through March 6, 2027.

In other recent news, Kestra Medical Technologies reported first-quarter fiscal 2027 revenue of $31 million, marking a 60% increase from the previous year and surpassing the consensus estimate of $29 million. Despite this revenue growth, the company posted a larger-than-expected loss of $0.75 per share, compared to analysts’ forecast of a $0.45 loss. The company improved its gross margin to 56.5% and raised its full-year revenue guidance from $137 million to $141 million. Analysts from Evercore ISI initiated coverage on Kestra Medical with an outperform rating, citing the company’s potential to capture market share in the wearable cardioverter defibrillator market. Piper Sandler reiterated an Overweight rating, emphasizing the strength of Kestra’s patent portfolio and potential platform extensions. Stifel also maintained a Buy rating, noting the strong revenue growth and increased sales guidance. These developments reflect Kestra Medical’s strategic positioning and ongoing advancements in its product offerings.